Jiang Saiping, Li Lu, Ru Renping, Zhang Chunhong, Rao Yuefeng, Lin Bin, Wang Rongrong, Chen Na, Wang Xiaojuan, Cai Hongliu, Sheng Jifang, Zhou Jianying, Lu Xiaoyang, Qiu Yunqing
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Hangzhou Xixi Hospital, Hangzhou 310023, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):158-169. doi: 10.3785/j.issn.1008-9292.2020.03.01.
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on ( 6), and -19: , we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
新型冠状病毒肺炎（COVID-19）重症和危重症患者通常伴有基础疾病，这导致特殊患者存在用药复杂、潜在药物相互作用及用药错误等问题。基于（6）以及-19：，我们总结了重症和危重症COVID-19患者使用抗病毒药物、糖皮质激素、血管活性药物、抗菌药物、益生菌、营养支持方案的经验。还建议重点关注药物管理，以评估药物疗效和治疗时长、预防和治疗药物不良反应、识别潜在药物相互作用、基于生物安全保护进行个体化用药监测以及特殊患者的给药。
